Short answer
Editas Medicine, Inc. (EDIT) filed an 8-K current report with the SEC on May 26, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events). Reg FD item contains only exhibit-furnishing language, not substantive company disclosure.
Editas Medicine, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Reg FD item contains only exhibit-furnishing language, not substantive company disclosure
- Information is furnished rather than filed, limiting Exchange Act Section 18 liability and incorporation by reference
Item 8.01 · Other Events
- EDIT-401 delivered approximately 90% mean reductions in LDL-C, Lp(a), and ApoB after one NHP dose
- LDL-C reduction reached at least 90% and remained durable through six months
- Therapeutically relevant 1.5 mg/kg dose showed 12.4% mean liver editing with no notable liver toxicity in non-GLP studies
- CTN submission planned for mid-2026, targeting first-in-human HeFH trial initiation later in 2026
- Early human proof-of-concept targeted by end-2026, but clinical and regulatory outcomes remain uncertain
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Editas Medicine, Inc. 8-K filings
Get the next EDIT 8-K as it lands
Follow EDIT for push alerts, or ask the research agent what this filing means.